HELEN ELAINE REMOTTI, M.D.

Plain English
This study looked at how combining two types of drugs—one that inhibits histone deacetylases (HDAC) and another that targets an RNA helicase called eIF4A—can fight pancreatic ductal adenocarcinoma (PDAC), a very aggressive type of cancer. The researchers found that this combination not only successfully reduced the cancer cells’ ability to survive but also did so at lower and safer doses, causing significant DNA damage in the cancer cells while sparing healthy tissue. This matters because it offers a new approach to treating a tough cancer without harming normal cells and could lead to more effective therapies. Who this helps: Patients with pancreatic cancer.

Plain English
This study looked at people with advanced pancreatic cancer who had not responded to other treatments, testing a new method of delivering a virus called talimogene laherparepvec (T-VEC) directly into tumors. Out of nine patients, 44% showed stable disease, and the average survival time was 7.8 months, with one patient living for 28 months. These findings are important because they suggest T-VEC can be safely used in this difficult-to-treat cancer, and further studies could improve treatment options. Who this helps: This helps patients with advanced pancreatic cancer looking for new treatment options.

Plain English
This study looked at how a type of liver cell, called hepatic stellate cells (HSCs), affects the liver's structure and function through a protein called R-spondin 3 (RSPO3). When the researchers removed HSCs, they found changes in liver regeneration and detoxification processes, leading to liver damage and a size increase. Specifically, removing Rspo3 produced similar harmful effects, including worsening liver diseases linked to alcohol and other metabolic issues. Who this helps: This research benefits patients with liver diseases, especially those linked to alcohol and metabolic disorders.

Plain English
This study looked at how the immune system responds to pancreatic ductal adenocarcinoma (PDAC) by analyzing blood samples from patients. Researchers found that 13 specific targets in the blood could clearly differentiate PDAC patients from healthy people, with most patients producing high levels of antibodies against phosphorylated amino acids, especially in those with advanced disease. These findings are significant because they highlight a potential avenue for developing immune-based treatments for this difficult-to-treat cancer. Who this helps: This helps patients with pancreatic cancer by paving the way for new therapies and better understanding of the disease.

Plain English
This study looked at the effectiveness of taking extra liver samples during surgery for children with biliary atresia when they had already had a needle biopsy before surgery. Researchers reviewed data from 116 patients and found that in 34.5% of cases, the results from the two types of biopsies did not match, with the additional biopsies often indicating worse liver damage. Overall, the type of biopsy did not show a clear link to how well the liver functioned a year after surgery, but younger age and lower liver enzyme levels were connected to better survival outcomes. Who this helps: This information helps pediatric surgeons and doctors providing care to children with biliary atresia.

Plain English
This study looked at a protein called CLDN18 in bile duct cancer, or cholangiocarcinoma, to see if it might be a target for new treatments. They found that about 13% of bile duct cancers showed high levels of this protein, similar to other cancers that have effective therapies available. This is important because it suggests that some patients with bile duct cancer could benefit from existing treatments that have been successful in other types of cancer. Who this helps: Patients with bile duct cancer who have high levels of CLDN18.

Plain English
This study looked at a drug called bethanechol to see if it could help patients with localized pancreatic cancer before they had surgery. Researchers found that although the drug didn't significantly change some specific cancer markers, it did reduce certain immune cells linked to inflammation and had no severe side effects, with most patients tolerating the treatment well. This matters because even small benefits in controlling inflammation could help improve outcomes for patients undergoing surgery for pancreatic cancer. Who this helps: This helps patients with pancreatic cancer before surgery.

Plain English
This study looked at how certain long noncoding RNAs (lncRNAs) help pancreatic cancer cells maintain their cancerous characteristics and resist changes that could make them less aggressive. Researchers found that when they blocked specific lncRNAs, cancer cells lost their malignant traits and became less capable of forming tumors. This is important because it highlights the potential for developing new treatments that target these lncRNAs to fight pancreatic cancer more effectively. Who this helps: Patients with pancreatic cancer could benefit from new treatments targeting these lncRNAs.

Plain English
This study focused on understanding a type of severe liver inflammation in children called indeterminate severe hepatitis (iSH) and how it compares to a related condition known as hemophagocytic lymphohistiocytosis (HLH). Researchers found that patients with iSH had signs of heightened immune system activity similar to those with HLH, and this activation was linked to the risk of worsening liver failure. Specifically, they discovered that the level of T-cell activation could predict if a patient with iSH might develop more severe liver problems, and using a certain antibody treatment helped improve liver function in some cases. Who this helps: This research benefits doctors and patients with indeterminate severe hepatitis by guiding treatment decisions.

Plain English
This study looked at whether a certain lab finding called erythrophagocytosis, which involves the ingestion of red blood cells by immune cells, could reliably help diagnose hemophagocytic lymphohistiocytosis (HLH) in patients undergoing liver biopsies. The researchers found that twelve liver pathologists were unable to agree on the presence of this finding, showing only 1.4% consistency in their assessments across 141 liver biopsy images. Because of this lack of agreement and the absence of a link to actual HLH cases, erythrophagocytosis is not a reliable indicator for diagnosing this serious condition. Who this helps: This helps doctors and medical professionals by clarifying that they should not rely on this lab finding when diagnosing HLH.

Plain English
This study explored how different types of cells in the liver use and produce fats and other small molecules by using a special imaging technique that can see them at a very detailed level. Researchers found that there are significant variations in these substances depending on the type of liver cell and its location in the liver, which emphasizes the complexity of liver function. Understanding these differences is important for developing targeted treatments for liver diseases. Who this helps: This helps patients with liver diseases by providing insights that can lead to better diagnosis and treatment options.

Plain English
This study looked at colorectal polyps, growths that can potentially turn into cancer, to understand how often they have concerning features, like being larger than 1 cm or showing signs of precancerous cells. Researchers examined nearly 2,700 polyps from over 1,800 patients and found that 5% had serious features, with rates varying significantly between hospitals—from 1.7% to 9.3%. The size of the polyp was the biggest factor linked to these advanced features, with larger polyps being much more likely to show them. Who this helps: This research benefits doctors and patients by highlighting the importance of polyp size in assessing cancer risk and improving screening evaluations.

Plain English
This study looked at rare pancreatic tumors called intraductal tubulopapillary neoplasms (ITPNs) to understand their characteristics better. Researchers examined three cases and discovered specific genetic changes: one had a KRAS variant, another had an FGFR2 fusion, and the third had a STARD3NL-BRAF fusion. Recognizing these differences is important because it helps doctors make better treatment decisions for patients, given that ITPNs have a more favorable outcome compared to other pancreatic tumors. Who this helps: This research helps patients with rare pancreatic tumors and their doctors by guiding treatment options.

Plain English
This study focused on a 35-year-old man with HIV who experienced severe rectal pain and bleeding due to Mpox infection. A medical examination revealed serious ulcers in his rectum, indicating that the virus can cause significant damage in that area. Understanding these effects is important because it highlights a serious complication of Mpox that may affect people, especially those with weakened immune systems. Who this helps: This helps patients with Mpox, particularly those with HIV or other immune issues.

Plain English
This study looked at how certain proteins, specifically TAZ and TEAD2, contribute to the growth of liver cancer (hepatocellular carcinoma or HCC). The researchers found that blocking TAZ led to a significant reduction in tumor growth and mortality in mice, while high levels of TAZ were linked to increased cancer cell growth in humans; about half of the patients with HCC showed TAZ and TEAD2 promoting tumor growth. This research is important because it identifies a potential new target for treatment, using TAZ and TEAD2, which could be used alongside existing therapies to better fight this aggressive cancer. Who this helps: Patients with liver cancer.

Plain English
This study looked at how a protein called angiopoietin-2 (ANGPT2) affects the growth of liver metastases in pancreatic neuroendocrine tumors (PanNETs), which are a type of cancer. The researchers found that high levels of ANGPT2 in patients were linked to worse survival rates, and blocking this protein in mice not only slowed tumor growth but also allowed more immune cells (T cells) to enter the tumors and work better against the cancer. This is important because improving immune response can help manage or reduce the severity of liver metastases, potentially increasing survival for patients. Who this helps: This benefits patients with pancreatic neuroendocrine tumors and their doctors.

Plain English
Researchers tested whether a painless ultrasound-based technique called vibration controlled transient elastography could reliably screen potential living donors for liver fat without requiring a biopsy. Among 79 donor candidates, the tool showed a meaningful correlation with MRI fat measurements and liver biopsy results, with acceptable sensitivity and specificity at defined score cutoffs. Integrating this screening step could reduce the number of invasive biopsies needed during donor evaluation.

Plain English
This study looked at how well current tests for DNA repair genes in gynecologic cancers, specifically using immunohistochemistry (IHC) and polymerase chain reaction (PCR), agree with each other. Researchers examined 328 cases and found that 98.2% of the test results matched, but in six cases, the tests gave conflicting results. By using advanced next-generation sequencing (NGS), they clarified these discrepancies and showed that choosing the right tumor sample for testing is crucial. Who this helps: This benefits patients with gynecologic cancers by ensuring they receive the correct treatments.

Plain English
This study looked at how a protein called TAZ in liver cells can lead to liver tumors in people with non-alcoholic steatohepatitis (NASH), a condition that can cause liver cancer. Researchers found that when they silenced TAZ in mice with NASH, the development of tumors was suppressed, showing a potential pathway involving DNA damage caused by TAZ. Specifically, changes in TAZ led to a gene called Cybb being activated, resulting in harmful DNA damage and tumor formation. Who this helps: This benefits patients with NASH and liver cancer, as targeted therapies could potentially prevent tumor development.

Plain English
This study looked at how neoadjuvant chemoradiation treatment affects the immune environment in patients with pancreatic ductal adenocarcinoma (PDAC). Researchers found that patients who received this treatment had more immune cells, specifically types of T cells, in their tumors compared to those who didn’t receive treatment. However, the study also revealed that T cells in PDAC tumors are organized differently than in melanoma, which could affect how effective these immune cells are in fighting the cancer, potentially leading to shorter survival times for some patients. Who this helps: This helps patients with pancreatic cancer and their doctors by providing insights into treatment responses and potential challenges of immunotherapy.

Plain English
This study looked at the role of specific cell types in the liver, called hepatic stellate cells (HSCs), in the development of liver cancer (hepatocellular carcinoma or HCC). Researchers found that while some HSCs help protect against liver cancer, others promote its growth by increasing stiffness in liver tissue and encouraging liver cell division. This shift in HSC types as liver disease progresses increases the risk of developing HCC in patients. Who this helps: This information benefits patients with chronic liver disease by providing insights into liver cancer risks and potential treatment targets.

Plain English
A teenager with liver cancer received immune checkpoint inhibitor therapy (anti-PD1) to shrink the tumor before a liver transplant. Despite concerns that this drug could trigger severe rejection after transplant, the graft remained stable and the patient did well. This case offers early evidence that checkpoint inhibitors may be safely bridged to transplantation in carefully selected pediatric patients.

Plain English
This study looked at a test called albumin in situ hybridisation (ISH) to see if it can help identify certain types of liver cancer in children, specifically hepatoblastoma and fibrolamellar hepatocellular carcinoma. Researchers found that albumin ISH accurately identified all cases of these cancers, achieving 100% sensitivity and specificity for both conditions, while another test called arginase-1 also performed perfectly, but the traditional test, HepPar 1, was less reliable. This matters because accurate diagnosis can lead to better treatment decisions for children with liver cancers. Who this helps: This helps pediatric patients with liver cancer and their doctors.

Plain English
This study looked at a protein called SATB2 to see how well it can help tell colorectal cancer apart from cancer in the lung, pancreas, and stomach. Researchers tested 335 cancer samples and found that 87% of colorectal cancers showed SATB2, while only a small percentage of cancers from other sites did—like 3% in lung and 2% in pancreatic cancers. This matters because it helps doctors more accurately diagnose colorectal cancer compared to other types, which can lead to better treatment decisions. Who this helps: This helps doctors and patients by improving cancer diagnosis.

Plain English
This study looked at how the PD-1 protein affects the development of stomach cancer in mice and the role of another protein, PD-L1. Researchers found that giving a treatment that blocks PD-1 reduced tumor size and increased immune cell involvement when given early, but had little effect once tumors were established. They also found that combining chemotherapy drugs with the PD-1 blocker improved immune response, but also led to higher levels of PD-L1, which actually promoted more tumor growth. Who this helps: This research helps cancer patients and their doctors understand how to better use immune therapies and chemotherapy for stomach cancer.

Plain English
This study looked at how consistently different expert pathologists diagnosed dysplasia (cell changes that can lead to cancer) in patients with inflammatory bowel disease (IBD). They found that the agreement among pathologists was fair to moderate, with a kappa score of 0.42, meaning that they often disagreed on the severity of dysplasia. Mentorship during training didn't significantly improve the accuracy of these diagnoses, which is important because consistent diagnosis is crucial for effective treatment of patients. Who this helps: This helps doctors and pathologists improve their diagnostic accuracy in IBD patients.

Plain English
Researchers studied how a protein called LIN28B affects colon cancer cells. They discovered that LIN28B enhances the expression of a key molecule called CDX2, which helps these cancer cells to differentiate, or mature, into a less aggressive form. Specifically, when LIN28B levels were increased, it led to growth patterns in tumors that resembled normal healthy tissue, indicating that better differentiation may lead to less aggressive cancer behavior. This is important because understanding how colon cancer cells differentiate can help in developing better treatment strategies. Who this helps: This helps patients with colorectal cancer and their doctors by providing insights for potential new treatments.

Plain English
This study looked at how certain cells in the liver, called cancer-associated fibroblasts (CAF), influence the growth of a specific type of liver cancer called intrahepatic cholangiocarcinoma (ICC). Researchers found that a specific group of these fibroblasts, mainly sourced from hepatic stellate cells, helps tumors grow faster, leading to worse outcomes for patients; notably, those with a high level of CAF had lower chances of survival and higher rates of cancer returning. Understanding these cell interactions provides potential targets for new treatments to slow down or stop this aggressive cancer. Who this helps: This helps patients with intrahepatic cholangiocarcinoma and their doctors.

Plain English
This study looked at two patients with a rare type of tumor in the gastrointestinal tract called ganglioneuroma. One patient had a large tumor that caused significant health issues, while the other had a smaller, less serious tumor with a better outcome. Understanding these differences is important because it helps doctors predict how these tumors might affect patients differently. Who this helps: Patients with ganglioneuroma and their doctors.

Plain English
This study looked at a type of heart disease called wild-type transthyretin cardiac amyloidosis (ATTRwt-CA), which is more common than people thought. Researchers found two patients who had heart issues along with liver problems, but their liver disease was due to a rare condition unrelated to their heart disease. This is important because it shows that doctors should consider different causes for liver problems in patients with this type of heart disease, rather than assuming the liver issues are just a result of heart failure. Who this helps: This primarily benefits doctors and healthcare teams treating patients with ATTRwt-CA.

Plain English
This study looked at how the stiffness of pancreatic tumors can help doctors diagnose pancreatic cancer and monitor how well treatments are working. Researchers found that as the cancer progressed, the stiffness measured using a special ultrasound technique increased: for instance, stiffness grew significantly as tumors developed from early-stage to advanced cancer. In patients who received chemotherapy, the stiffness of tumors decreased, indicating a positive response to the treatment. Who this helps: This research benefits patients with pancreatic cancer and their doctors by providing a potential way to better assess the disease and treatment effects.

Plain English
This study examined the liver damage seen in 40 patients who died from COVID-19. The researchers found that three-quarters of the patients had a condition called macrovesicular steatosis, which means there was significant fat buildup in the liver. Additionally, liver enzymes were elevated, indicating liver injury, with peak levels reaching 68 U/L for one enzyme and 102 U/L for another, both higher than normal. This research is important because it highlights that COVID-19 can severely affect the liver, which is important for understanding the full impact of the virus on health. Who this helps: Patients and doctors working with those who suffer from severe COVID-19 complications.

Plain English
This study looked at a new protein called HHLA2 in pancreatic cancer and found that it is present in a majority of pancreatic cancer cases, showing up in 95% of early precancerous lesions and 77% of invasive cancer cases. The research indicates that higher levels of HHLA2 are linked to better survival after surgery. Understanding HHLA2’s role could lead to new treatments for pancreatic cancer, which is often hard to treat. Who this helps: This benefits patients with pancreatic cancer and their doctors.

Plain English
This research focused on a protein called FLI1 in stomach cancer, specifically gastric adenocarcinoma. The study found that levels of FLI1 were much lower in cancerous tissues compared to normal tissues, and patients with higher FLI1 levels tended to live longer. When FLI1 was artificially increased in cancer cells in the lab, their ability to grow and invade other tissues decreased significantly—by about 74% and 32% respectively. Who this helps: This helps patients with gastric adenocarcinoma, as it identifies a potential biomarker for survival and a target for treatment.

Plain English
This study looked at a new treatment for nonalcoholic steatohepatitis (NASH), a serious liver condition that currently has no approved drugs. Researchers found that injecting a specially designed small interfering RNA (siRNA) targeting a molecule called TAZ significantly reduced liver inflammation and damage in mice with NASH. Specifically, this treatment both prevented the disease from worsening and helped to improve conditions in mice that already had NASH, showing it could be a promising approach for human patients. Who this helps: This helps patients with nonalcoholic steatohepatitis.

Plain English
This study looked at the potential for DNA contamination in a common method used in medical testing called plasma-thrombin cell blocks. Researchers found that all 20 samples of plasma tested contained amplifiable DNA, with the DNA quality being good enough for testing (up to 600 base pairs). This is important because the DNA from plasma could interfere with tests that detect important genetic information, especially in cases where the sample has very few cells. Who this helps: This helps doctors and patients who rely on accurate molecular testing results for diagnosing conditions like cancers.

Plain English
This study looked at pediatric liver tumors and found that many tumors previously classified as a type of liver cancer called small cell undifferentiated hepatoblastoma (SCUD-HB) are actually a more aggressive tumor called malignant rhabdoid tumor (MRT). Out of the six cases studied, four were wrongly labeled as SCUD-HB, highlighting a misclassification issue. It’s important to change the classification because the treatments for SCUD-HB do not work on MRT, which can lead to worse outcomes for patients. Who this helps: This helps doctors and patients by improving tumor diagnoses and treatment options.

Plain English
This study looked at how HER2, a protein linked to cancer growth, is expressed in biopsies (small tissue samples) compared to larger tissue samples (resections) in patients with advanced gastroesophageal cancers. Out of 100 patients tested, 60% had biopsies that were initially negative or uncertain for HER2 but showed signs of HER2 overexpression when larger samples were examined, potentially impacting treatment eligibility. This is important because accurately assessing HER2 can help doctors determine who may benefit from targeted treatments that improve survival outcomes. Who this helps: This helps patients with advanced gastroesophageal cancers by ensuring they receive the best possible treatment based on accurate HER2 testing.

Plain English
This paper looks at rare pancreatic tumors, which don't always have clear signs that make them easy to identify. The authors emphasize that using imaging tests, along with lab results and patient history, helps doctors make the right diagnosis and treatment plan. Understanding these tumors better is crucial because it can improve how patients are managed and treated. Who this helps: This helps patients with rare pancreatic tumors and their doctors.

Plain English
This study looked at how stress hormones called catecholamines affect the growth of pancreatic cancer. Researchers found that these hormones promoted cancer growth by increasing a protein that supports nerve development, leading to more nerves around the tumors and faster tumor growth in mice. When they blocked the receptor involved or combined treatments with existing cancer drugs, they saw improved survival rates in the mice. In cancer patients, higher levels of a specific growth factor were linked to more nerve density and better survival for those taking certain beta-blockers. Who this helps: This benefits patients with pancreatic cancer and their doctors by providing new insights into treatment options.

Plain English
This research studied a specific type of cell called DCLK1 cells and their role in the development of pancreatic tumors in mice. The scientists found that DCLK1 cells come from a different origin than other cells related to pancreatic cancer and appear early in the process before tumors form, providing insight into how these tumors might start. Understanding the role of these cells is important because it could help in the early detection and treatment of pancreatic cancer. Who this helps: This helps patients at risk of pancreatic cancer and their doctors.

Plain English
This study looked at patients with lysosomal acid lipase deficiency (LAL-D) who received liver transplants. Among 18 cases examined, 61% experienced a return of disease symptoms, and 33% died after transplantation. While liver transplants can help patients with liver failure, the study found that they do not stop the disease's progression because the underlying problem is related to a lack of an important enzyme. Who this helps: Patients with lysosomal acid lipase deficiency and their doctors.

Plain English
This study focused on finding better drug treatments for neuroendocrine tumors, which are rare cancers that start in the pancreas and digestive system. Researchers tested 107 different drugs and found that one specific drug, entinostat, effectively inhibited cancer growth in 42% of patients with advanced forms of these tumors. This approach helps tailor treatments to individual patients, which can lead to more effective care. Who this helps: This benefits patients with gastroenteropancreatic neuroendocrine tumors.

Plain English
This study investigated how signals from the vagus nerve, which is part of the body's parasympathetic system, affect the growth of pancreatic cancer in mice. Researchers found that when the vagus nerve was cut, pancreatic cancer grew faster, but giving the mice a drug called bethanechol helped slow this growth and even extended survival by a significant amount. This is important because it shows that boosting signals from the vagus nerve may help treat pancreatic cancer, especially by targeting specific pathways involved in tumor growth. Who this helps: Patients with pancreatic cancer.

Plain English
This case report describes an 18-month-old girl with three simultaneous rare conditions — autosomal recessive polycystic kidney disease, Caroli syndrome, and hepatoblastoma — successfully treated with surgical resection alone without chemotherapy. Nine years later she remained tumor-free with stable kidney function. The case adds to a limited literature on managing concurrent pediatric liver tumors and cystic kidney disease.

Plain English
This study looked at how to best analyze microRNAs in liver cancer, specifically hepatocellular carcinoma (HCC), to accurately identify those that are abnormal. Researchers found that using a specific method to normalize data helped consistently identify 14 key microRNAs linked to HCC, including two new ones, miR-324-5p and miR-550, which are important for understanding the disease. This is important because finding the right approach for measuring these molecules can enhance research and improve diagnostic tools in liver cancer. Who this helps: This helps patients and doctors by improving cancer diagnosis and treatment strategies.